Since purchasing cell and gene therapy CDMO MaSTherCell early last year, Catalent has been on an M&A tear in Belgium. With yet another deal, it’s bring...

Minor League Baseball is looking for a home run with a new pharma tie-up. Stryker joins the league's roster as the official joint replacement partner, looking t...

Pfizer and Merck KGaA’s Bavencio is the only PD-1/L1 drug allowed to treat bladder cancer patients who’ve responded to one round of chemo. But patients in England wo...

Europe’s drug regulator says it’s evaluating an assortment of potential side effects following inoculation with leading COVID-19 vaccines, including heart inflammati...

As the second leg of AstraZeneca’s immuno-oncology plan, tremelimumab hasn’t exactly lived up to its expectations. After multiple flops that cast serious doubts over...

Cancer and autoimmune diseases aren’t going anywhere. And so the scramble to develop next-gen treatments rages on. As a result, global spending on oncology and imm...

Last May, Acella Pharmaceuticals pulled 13 lots of its prescription hypothyroidism med NP Thyroid in the U.S. after testing revealed an excess of one of the drug's&n...

Novavax and Europe appear to be close to finalizing a COVID-19 vaccine supply deal. The Gaithersburg, Maryland-based biotech has told the bloc that it plans to beg...

In the first three months of 2021, Pfizer's COVID-19 vaccine pulled in as much revenue as some pharma blockbusters make in an entire year. That’s just the begin...

With plans to boost COVID-19 vaccine production into the billions of doses next year, Moderna is making major renovations at its Massachusetts manufacturin...